Reversible covalent direct thrombin inhibitors.
Sivaraja, M., Pozzi, N., Rienzo, M., Lin, K., Shiau, T.P., Clemens, D.M., Igoudin, L., Zalicki, P., Chang, S.S., Estiarte, M.A., Short, K.M., Williams, D.C., Datta, A., Di Cera, E., Kita, D.B.(2018) PLoS One 13: e0201377-e0201377
- PubMed: 30071045 
- DOI: https://doi.org/10.1371/journal.pone.0201377
- Primary Citation of Related Structures:  
6CYM - PubMed Abstract: 
In recent years, the traditional treatments for thrombotic diseases, heparin and warfarin, are increasingly being replaced by novel oral anticoagulants offering convenient dosing regimens, more predictable anticoagulant responses, and less frequent monitoring. However, these drugs can be contraindicated for some patients and, in particular, their bleeding liability remains high.
Organizational Affiliation: 
Verseon Corporation, Fremont, California, United States of America.